Novavax
$8.88
24H
Market Cap
Volume
Supply
Price Chart
About Novavax - NVAX
Novavax, Inc. is a biotechnology company focused on developing vaccines to address a wide range of infectious diseases, including flu and COVID-19. Their product pipeline often includes vaccine candidates created with proprietary nanoparticle technology and a saponin-based Matrix-Mâ„¢ adjuvant to enhance immune responses.
What are Novavax's core values and mission statement?
Novavax, Inc. is dedicated to improving global health through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Their core values emphasize a commitment to patient well-being, integrity in their science and interactions, and teamwork to achieve shared goals in public health.
Who founded Novavax and when?
Novavax, Inc. was founded in 1987 by Stanley Erck, John Spears, and a team of other scientists.
Who leads Novavax?
As of the time of this response, Novavax, Inc. is led by Stanley C. Erck, who serves as the President and CEO of the company.
Where is Novavax located, and what is its base country?
Novavax, Inc. is headquartered in Gaithersburg, Maryland, United States.
On which exchanges is Novavax traded?
Novavax, Inc. is traded on the Nasdaq Stock Market under the ticker symbol NVAX.
Historical data
Novavax (NVAX) Price Live Data
The live price of Novavax (NVAX) is $8.88, with a trading volume of 3,218,528 in the last 24 hours. Wrapstocks updates the NVAX price in real-time. Novavax is down -3.32% in the last 24 hours. The company has a live market cap of $1,420,834,304.00 and a supply of 160,094,006 NVAX stocks.
Novavax (NVAX) is traded on NASDAQ Stock Exchange, and currently, the market is open; trading will be paused in 47 minutes.
